Eradivir

Our overarching goal is to focus the power of a patient’s immune system to kill both viruses and virus-infected cells, thereby eliminating a viral infection without causing damage to any uninfected cells. To achieve this, we employ a novel bispecific immunotherapy that eradicates a virus by tethering a patient’s cytotoxic immune cells specifically to the pathogenic virus or virus-infected cell, i.e. facilitating the rapid and selective destruction of the virus by the patient’s immune system. With a toolkit of these small bispecific molecules, we will be able to treat and potentially cure influenza, multiple coronaviruses, hepatitis B, HIV, and even cancers without damaging a patient’s healthy cells.